Research Options: Select below IPO Calendar	Week of Expected Pricing Withdrawn Company Name Clarus therapeutics Inc. Proposed Ticker CLRS CUSIP 182717108 Business Description A pharmaceutical company focused on the development and commercialization of OriTex, our Phase III-ready, first-in-class oral testosterone, or T, replacement therapy. Lead Underwriter Piper Jaffray & Co., Wells Fargo Securities, LLC Co-Managers Lazard Capital Markets LLC , Needham & Company, LLC Initial Shares 5,000,000 Revised Initial Shares N/A Initial Price $11.00-$13.00 Revised Price N/A Final Price N/A Final Ticker N/A
	© 2024 ICE Data Services. All rights reserved.